Leverages a predictive algorithm to significantly improve the success rate of peptide synthesis, especially for challenging peptides. This innovation ensures the most efficient approach, leading to better and faster outcomes.
Primary screening services cater to the specific needs of PCV development, offering flexible solutions that guarantee reliable peptides suitable for any phase of development.
Having served over 300 academic and industrial customers. NeoPre has consistently delivered superior results. Clients attest to our high success rates (99%) and quick turnaround, with delivery time as fast as 4 weeks.
Our facility includes a Grade A isolator dedicated to achieve sterile filtration and aseptic filling assisting human injection purposes.
With a strong track record, we've successfully delivered 60+ batches to 20+ companies . Our adaptable GMP manufacturing capabilities guarantee reliability and quality for each project.
We aim to provide affordable solutions without compromising on quality, offering rapid delivery that meets the needs of both patients and research organizations.
Screening hundreds of neoantigens in mice to validate the generalizability of SNP-7/8a was a tremendous
undertaking that could not have been possible without the diligent efforts of GenScript's peptide chemists
who were able to rapidly synthesize even the most challenging sequences at the high purity required.
The 3T technology is multi-faceted due to the ability to uncover specialties in any T-cell- mediated disease. 3T Biosciences has been working with GenScript since 2017 to generate thousands of peptides to understand how T-cell receptors recognize their targets. With that information we can better understand how to identify novel targets in solid tumors and generate safe and effective T-cell receptors.
GenScript’s neoantigen solution streamlines the development of personalized cancer vaccines, offering fast, reliable results at every stage—from design and screening to GMP production and clinical trials—accelerating your path to clinical application.
Nature Interview with 3T Biosciences: Using Neoantigen Peptides for Personalized T cell therapy
Nature Interview with 3T Biosciences: Using Neoantigen Peptides for Personalized T cell therapy
Interviews: Neoantigen-based precision therapeutics
Interviews: Neoantigen-based precision therapeutics
Editorials: Neoantigens: presenting new vaccine opportunities in immuno-oncology
Editorials: Neoantigens: presenting new vaccine opportunities in immuno-oncology
Editorials: Neoantigen Peptides in Precision Medicine
Editorials: Neoantigen Peptides in Precision Medicine
Podcast Review: Personalized cancer vaccine prospects improve with self-assembling nanoparticles
Podcast Review: Personalized cancer vaccine prospects improve with self-assembling nanoparticles
Neoantigens are new cancer antigens expressed in tumor tissue but not in healthy tissue. They are unique to individual tumors and make ideal targets for personalized immunotherapies. Neoantigens are generated through mutations and are highly specific. They are not recognized as self-antigens, leading to a strong immune response.
Neoantigens, unlike common tumor-associated antigens, are not recognized as self-antigens and therefore elicit a strong immune response. Directly targeting neoantigens can enhance their immunogenicity and stimulate a potent anti-tumor immune response. Once a neoantigen forms, it is unlikely to mutate again and escape therapeutic targeting. Personalized cancer vaccines that target multiple neoantigens simultaneously can prevent immune escape if one neoantigen mutates. Each neoantigen can be matched to specific T cell receptors, allowing for in vitro analysis of their immune response before potential therapeutic use.
Neoantigen peptides usually vary in length, charge and hydrophobicity leading to difficulties in synthesis and purification. So, GenScript has developed the NeoPre algorithm, which is able to determine the peptide synthesis difficulty based on sequence alone. With the NeoPre algorithm, we are able to synthesize neoantigen peptides with over 98% success rate. We also have a great turnaround time of overall about 10 days. Once your peptides have been generated, GenScript offers library design tools such as alanine scanning, overlapping, T-cell truncation to assist you optimize any neoantigen sequence. So, these are the advantages of using our Neoantigen peptide as we promise to provide a one stop solution for all our peptide users.
GenScript is able to provide neoantigen peptides with length up to 35 AA with purity> 95% and compliance GMP requirement to succeed your clinical trials.
Neoantigen peptides are difficult to be produced due to several factors. Firstly, their length can vary, with some being 9-11 amino acids long and others exceeding 25 amino acids. Peptides with over 20 amino acids are particularly challenging to synthesize. Secondly, neoantigens may contain charge-modifying amino acids that are not commonly found in natural tumor-associated antigens. This can make synthesis more difficult as specific isoelectric points are required for certain synthetic steps. Thirdly, the random amino acid insertions or deletions that generate neoantigens often introduce hydrophobic side chains, leading to increased aggregation and limited solubility in water. Purification becomes challenging as a result. Additionally, different applications within therapeutic development require varying yields, mass, purity, and percentage of target peptide, making it cumbersome to find a reliable provider that can accommodate these diverse requirements. GenScript has tailored its neoantigen peptide service to address these challenges and provide high-quality hydrophobic peptides as needed.
GenScript has the capacity to begin your Neoantigen peptide synthesis project without any waiting time. Contact our commercial team to ensure your project stays on schedule.
Based on difficulty and project details we help you pick the applicable synthesis platform to maximize success. It can be microwave technology, liquid-phase technology or solid-phase technology.
All GenScript peptides undergo Total Quality Management testing through AccuPep™ quality control services. We provide more than 14 types of QC.
We can produce non-sterile neoantigen peptide in the RUO line and GMP facility. In case the sterile neoantigen peptide is requested, our GMP facility with Sterility Assurance (sterilizing filtration and fill/finish in Class A isolator) could reach.
GenScript is able to provide up to 35 AA.
Each batch of Neoantigen peptide is up to 150mg.
Yes, GenScript has developed a predictive algorithm, NeoPre , which is able to determine peptide synthesis difficulty based on sequence alone. NeoPre can then recommend the most efficient approach to synthesizing peptides using one of GenScript’s many synthesis platforms.